Amarin Corporation plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMRN research report →
Companywww.amarincorp.com
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers.
- CEO
- Aaron D. Berg
- IPO
- 1993
- Employees
- 275
- HQ
- Dublin, IE
Price Chart
Valuation
- Market Cap
- $293.70M
- P/E
- -8.79
- P/S
- 1.37
- P/B
- 0.66
- EV/EBITDA
- -74.54
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 52.48%
- Op Margin
- -17.38%
- Net Margin
- -15.64%
- ROE
- -7.34%
- ROIC
- -7.76%
Growth & Income
- Revenue
- $213.65M · -6.55%
- Net Income
- $-38,798,000 · 52.79%
- EPS
- $-1.80 · 55.00%
- Op Income
- $-13,941,000
- FCF YoY
- 121.74%
Performance & Tape
- 52W High
- $20.90
- 52W Low
- $10.66
- 50D MA
- $14.72
- 200D MA
- $15.46
- Beta
- 0.82
- Avg Volume
- 72.17K
Get TickerSpark's AI analysis on AMRN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 18, 26 | Bonfiglio Patrice Eadon | other | 838 |
| Apr 18, 26 | Bonfiglio Patrice Eadon | other | 838 |
| Apr 18, 26 | Bonfiglio Patrice Eadon | other | 403 |
| Apr 18, 26 | Cohen Paul | other | 838 |
| Apr 18, 26 | Cohen Paul | other | 838 |
| Apr 18, 26 | Cohen Paul | other | 403 |
| Apr 18, 26 | Sterling Louis III | other | 838 |
| Apr 18, 26 | Sterling Louis III | other | 403 |
| Apr 18, 26 | Sterling Louis III | other | 838 |
| Apr 18, 26 | Odysseas Kostas D | other | 838 |
Our AMRN Coverage
We haven't published any research on AMRN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AMRN Report →